Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease

Goh Tanaka 1*, Taisuke Jo 1,2, Hiroyuki Tamiya 1, Yukio Sakamoto 1, Wakae Hasegawa 1, Hiroki Matsui 3, Kiyohide Fushimi 4, Hideo Yasunaga 3 and Takahide Nagase 1

Abstract

Background: The incidence and prevalence of non-tuberculous mycobacterial pulmonary disease (NTM-PD) are reportedly increasing in many parts of the world. However, there are few published data on NTM-PD-related death. Using data from a national inpatient database in Japan, we aimed in this study to identify the characteristics of patients with NTM-PD and clinical deterioration and to identify risk factors for in-hospital mortality.

Methods: We examined data from the Diagnosis Procedure Combination (DPC) database in Japan from July 2010 to March 2014. We extracted data for HIV-negative NTM-PD patients who required unscheduled hospitalization. We evaluated these patients’ characteristics and performed multivariable logistic regression analysis to identify risk factors for all-cause in-hospital mortality.

Results: A total of 16,192 patients (median age: 78 years; women: 61.2%) were identified. The median body mass index (BMI) was 17.5 kg/m² (IQR 15.4–20.0). All-cause in-hospital death occurred in 3166 patients (19.6%). The median BMI of the patients who had died was 16.0 kg/m² (IQR 14.2–18.4). Multivariable analysis revealed that increased mortality was associated with male sex, lower BMI, lower activities of daily living scores on the Barthel index, hemoptysis, and comorbidities, including pulmonary infection other than NTM, interstitial lung disease, pneumothorax, and malignant disease.

Conclusions: We found associations between being underweight and having several comorbidities and increased in-hospital mortality in patients with NTM-PD. Preventing weight loss and management of comorbidities may have a crucial role in improving this disease’s prognosis.

Keywords: Non-tuberculous mycobacterial disease, Hospital mortality, Body mass index

Background

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) usually develops in middle-aged and older individuals, and is generally intractable and slowly progressive. The incidence and prevalence of NTM-PD are reportedly increasing in many parts of the world [1–7].

Increasing numbers of NTM-PD-related deaths among HIV-uninfected patients has also been reported in Japan [2] and the USA [8]. NTM-PD related deaths are expected to be a significant health problem in countries in which the population is aging.

Several population-based studies have identified the risk factors of male sex, older age, and some comorbidities for NTM-PD-related deaths [8–11]. Clinical conditions such as low body mass index (BMI) have also been shown to be associated with poor long-term prognosis.
of NTM-PD in some hospital-based studies [12, 13]; however, these studies had small patient cohorts. With regard to the significance of clinical deterioration of patients with NTM-PD, little information is available, particularly on in-hospital deaths. Evaluating risk factors for in-hospital mortality is crucial to improving the prognosis in patients with NTM-PD.

In this study, we used data from a nationwide database in Japan to investigate the characteristics and comorbidities of patients with NTM-PD who required unscheduled hospitalization and examined factors associated with in-hospital mortality in these patients.

**Methods**

**Data source**

We examined data from the Diagnosis Procedure Combination (DPC) database in Japan from July 2010 to March 2014. The database includes administrative claims data and discharge abstract data from more than 1200 hospitals, which covered 50% of the total bed capacity of acute care hospitals during the survey period. Primary diagnoses and comorbidities are recorded using International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) codes, accompanied by text data in Japanese. The database also contains the following information: age, sex, body height and weight, smoking status, grade of activity of daily living expressed as Barthel index score on admission, discharge status, therapeutic procedures, and medication use during hospitalization. This study was approved by the Institutional Review Board of The University of Tokyo and was performed in accordance with the Declaration of Helsinki. The requirement for informed consent was waived because of the anonymous nature of the data.

**Patient selection and data**

We retrospectively extracted data for patients with ICD-10 code: A310 (pulmonary mycobacterial infection) and A319 (Mycobacterial infection, unspecified). We did not include patients who were diagnosed with NTM extrapulmonary disease (ICD-10 code, A311 and A318) during the study period. We included only the last hospitalization of patients who required unscheduled hospitalization more than once during the study period. We excluded patients < 18 years of age and those with HIV infection (ICD-10 code, B20–B24). We identified comorbidities using ICD-10 codes, as shown in Table 1. Because it is difficult to distinguish between primary bronchiectasis and bronchiectasis secondary to NTM-PD [14], we did not include the comorbidity of bronchiectasis in our study.

To evaluate weight loss, we categorized BMI in accordance with the levels of severity of anorexia nervosa in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [15].

We used either ICD-10 codes (R042, R048, and R049) or treatment with intravenous hemostatic agents (carbozochrome sodium sulfonate and/or tranexamic acid) as indicators of clinically significant hemoptysis or bloody sputum. We then excluded patients with diagnoses of hemorrhage from organs other than lungs (ICD-10 codes shown in Table 2) and those who had undergone endoscopic procedures for hemostasis of gastrointestinal

### Table 1 ICD-10 codes used to identify comorbidities

| Comorbidity                      | ICD-10 codes                  |
|----------------------------------|-------------------------------|
| Pulmonary infection              | J100, J110, J12–J18, J20–22, J85, J86, J690 |
| Pulmonary aspergillosis          | B44                           |
| COPD                             | J43, J440, J441, J449         |
| Bronchial aspergillosis          | J45, J46                      |
| Interstitial asthma              | J841, J848, J849              |
| Pneumothorax                     | J93                           |
| Congestive heart failure         | I110, I500, I501, I509        |
| Ischemic heart disease           | I20–I25                       |
| Cerebrovascular disease          | I60–I69                       |
| Renal disease                    | N00–08, N10–N19               |
| Autoimmune disease               | M05, M06, M08, M30–M35        |
| Diabetes mellitus                | E10–E14                       |
| Bone fracture                    | S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T10, T12 |
| Lung cancer                      | C33, C34                      |
| Hematological malignancy         | C81–C85, C88, C90–C96         |
| Other malignant disease          | C00–C97                       |
tract bleeding. We considered that arterial embolization performed in patients with hemoptysis was bronchial artery embolization.

In addition, we extracted data concerning oral and intravenous treatment with various drugs, including corticosteroids and anti-mycobacterial agents. We evaluated prescription of the following antibiotics: rifamycins, including rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin, and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin. We then assessed the combination of rifamycin, ethambutol, and clarithromycin, which is the recommended first line therapy for *Mycobacterium avium* complex pulmonary disease (MAC-PD) in Japan [16]. We also evaluated prescription of erythromycin, which has an anti-inflammatory effect in patients with chronic airway diseases.

### Results

#### Patient characteristics

We identified 16,280 patients with NTM-PD who required unscheduled hospitalization during the study period. We then excluded 24 patients aged < 18 years and 64 patients with HIV infection from the study, leaving 16,192 patients who were eligible for further analysis.

These patients characteristics are shown in Table 3. The median age was 78 years (IQR 71–84) and 61.2% were women. The overall median BMI was 17.5 kg/m² (IQR 15.4–20.0), being 18.1 kg/m² (IQR 15.9–20.6) for men and 17.2 kg/m² (IQR 15.2–19.5) for women.

### Statistical analysis

We used χ² tests to compare baseline characteristics, treatments, and procedures during hospitalization between patients who died during hospitalization and those who survived. We performed multivariable logistic regression to identify risk factors for all-cause in-hospital mortality. We used multiple imputation by the chained equations technique to deal with missing data on BMI, smoking history, and Barthel index scores. We included all the variables analyzed in this study in the imputation model and created 20 imputed datasets. We fitted multivariable logistic regression analyses for in-hospital mortality with generalized estimating equations to account for within-hospital clustering [17]. We obtained one set of statistical results on each imputed dataset and integrated them using Rubin’s combination rules [18]. We set statistical significance at less than 0.05 for all analyses. We performed statistical analyses using Stata/MP version 14 (StataCorp, College Station, TX, USA).

| ICD-10 codes |
|----------------|
| N288, N300, N304, N309, N328, N368, N421, N421, N488, N501, E274 |
| N645, N830, N831, N838, N908, N921–N924, N930, N938, N939, N950, N988, O209, O441, O469, O679, O695, O720–O722, O730, O731 |
| E078, H603, H669, H738, H922, R040, R041 |
| I60–I62 |
| G951, G968 |
| H113, H168, H208, H210, H313, H350, H356, H357, H405, H431, H448, H470 |
| S013, S051, S063, S066, S068, S098, S368, S378, T144, T794 |
| T810, T811 |

### Treatments during hospitalization

Treatments during hospitalization are shown in Table 4; 44.6% of the 16,192 patients had not received any antibiotics with antimicrobial activity against NTM during the hospitalization, 3.2% had received monotherapy with erythromycin, and 15.2% had been treated with combination therapy including rifamycin, ethambutol and clarithromycin. Corticosteroids were prescribed for 20.9% of all patients.

### All-cause in-hospital mortality

Overall, 3166 patients (19.6%) died during their unscheduled hospitalizations (Table 3). The median age of these patients was 80 years (IQR 74–85). The median BMI of all patients who died in hospital was 16.0 kg/m² (IQR 14.2–18.4), comprising 16.6 kg/m² (IQR 14.8–19.1) for men and 15.4 kg/m² (IQR 13.7–17.6) for women. The median length of hospital stay was 18 days (IQR 10–34) in all patients and 21 days (IQR 8–44) in patients...
Table 3 Baseline characteristics of patients with NTM pulmonary disease who required unscheduled hospitalization

|                        | Total (%) | Death (%) | P-value |
|------------------------|-----------|-----------|---------|
|                        | n = 16,192| n = 3166  |         |
| **Sex**                |           |           | < 0.001 |
| Male                   | 6283 (38.8)| 1543 (48.7)|         |
| Female                 | 9909 (61.2)| 1623 (51.3)|         |
| **Age, years**         |           |           | < 0.001 |
| < 70                   | 3400 (21.0)| 455 (14.4)|         |
| 70–79                  | 5374 (33.2)| 1035 (32.7)|         |
| ≥ 80                   | 7418 (45.8)| 1676 (52.9)|         |
| **BMI, kg/m²**         |           |           | < 0.001 |
| < 15.0                 | 2858 (17.7)| 910 (28.7)|         |
| 15.0–15.9              | 1627 (10.0)| 371 (11.7)|         |
| 16.0–16.9              | 1714 (10.6)| 297 (9.4)|          |
| 17.0–18.4              | 2533 (15.6)| 365 (11.5)|          |
| 18.5–24.9              | 5036 (31.1)| 568 (17.9)|          |
| ≥ 25.0                 | 476 (2.9)| 44 (1.4)|          |
| **Missing data**       | 1948 (12.0)| 611 (19.3)|          |
| Activities of daily living, Barthel index | | | < 0.001 |
| 100                    | 5137 (31.7)| 354 (11.2)|         |
| 75–95                  | 1553 (9.6)| 159 (5.0)|          |
| 50–70                  | 1921 (11.9)| 336 (10.6)|          |
| 25–45                  | 1225 (7.6)| 296 (9.3)|          |
| 0–20                   | 3818 (23.6)| 1426 (45.0)|         |
| **Missing data**       | 2538 (15.7)| 595 (18.8)|          |
| **Smoking history**    |           |           | < 0.001 |
| No                     | 11,373 (70.2)| 2083 (65.8)|         |
| Yes                    | 3167 (19.6)| 668 (21.1)|          |
| **Missing data**       | 1652 (10.2)| 415 (13.1)|          |
| **Symptom**            |           |           |         |
| Hemoptysis             | 2996 (18.5)| 528 (16.7)| 0.003 |
| **Comorbidity**        |           |           |         |
| Pulmonary disease      |           |           |         |
| Pulmonary infection    | 8225 (50.8)| 2024 (63.9)| < 0.001 |
| Pulmonary aspergillosis| 874 (5.4)| 261 (8.2)| < 0.001 |
| COPD                   | 1527 (9.4)| 362 (11.4)| < 0.001 |
| Bronchial asthma       | 1158 (7.2)| 181 (5.7)| < 0.001 |
| Interstitial lung disease | 1171 (7.2)| 384 (12.1)| < 0.001 |
| Pneumothorax           | 730 (4.5)| 183 (5.8)| < 0.001 |
| Non-pulmonary disease  |           |           |         |
| Congestive heart failure | 2279 (14.1)| 650 (20.5)| < 0.001 |
| Ischemic heart disease | 1123 (6.9)| 184 (5.8)| 0.006 |
| Cerebrovascular disease | 1248 (7.7)| 243 (7.7)| 0.94 |
| Renal disease          | 853 (5.3)| 218 (6.9)| < 0.001 |
| Autoimmune disease     | 1225 (7.6)| 198 (6.3)| 0.002 |
| Diabetes mellitus      | 2289 (14.1)| 460 (14.5)| 0.48 |
who died during hospitalization. Two-thirds of the patients who required mechanical ventilation died during the hospitalization (Table 4).

Table 5 shows the results of the multivariable logistic regression analysis for all-cause in-hospital mortality. Higher in-hospital mortality was associated with male sex, lower BMI, lower Barthel index score, hemoptysis, and comorbidities, including pulmonary infection other than NTM, pulmonary aspergillosis, interstitial lung disease, pneumothorax, congestive heart failure, renal disease, and malignant disease.

Discussion
In this study, we analyzed in-hospital mortality using data of more than 16,000 patients with NTM-PD drawn from a nationwide database in Japan. Pulmonary diseases accounted for 68.3% of primary diagnoses during these patients’ hospitalizations. The results of multivariable logistic regression analysis showed that male sex, lower BMI, lower Barthel index score, and hemoptysis were associated with higher in-hospital mortality. Several comorbidities were also associated with higher mortality. Several previous population-based studies have evaluated risk factors for NTM-related deaths. These studies identified older age [8, 9, 11, 19] and male sex [9–11, 19] as potential risk factors for NTM-related deaths. Several comorbid diseases were also shown to be possible risk factors, including chronic obstructive pulmonary disease (COPD) [8, 11], lung cancer [10, 11, 19], bronchial asthma [10], pneumonia [10], and interstitial lung disease [11]. Bloody sputum was also associated with mortality in one single center study [20].

In the present study, we found that most of the participants (50.8%) had comorbid pulmonary infections in addition to NTM. Furthermore, pulmonary infection was significantly associated with in-hospital mortality, whereas, COPD and bronchial asthma were not. It remains unknown why COPD and bronchial asthma were not associated with higher in-hospital mortality. One possibility is that some of the patients hospitalized for exacerbations of COPD or bronchial asthma had better treatment responses.

Almost 90% of NTM-PD in Japan is reportedly MAC-PD [3]. In the present study, 15.2% of the patients received combination therapy including rifampicin, ethambutol, and clarithromycin, which is a standard regimen for MAC-PD, whereas 44.6% did not receive any antibiotics that target NTM. It seems likely that a relatively large proportion of patients in our study required unscheduled hospitalization for management of comorbid diseases or conditions.

In a previous study of 178 patients with NTM-PD from Oregon, USA, regular use of immunosuppressive medication was a risk factor for death [19]. In our study, about one third of patients who received corticosteroids after admission died during hospitalization. It is possible that most of the patients who were treated with corticosteroids had severe comorbidities on admission. Further studies are needed to elucidate the association between regular use of corticosteroids and prognosis of NTM-PD.

This study included BMI data in the multivariable analysis for mortality; to the best of our knowledge, no published studies have examined BMI prior to death in patients with NTM-PD. However, several studies have reported an association between weight loss and

### Table 3 Baseline characteristics of patients with NTM pulmonary disease who required unscheduled hospitalization (Continued)

| Total (%) | Death (%) | P-value |
|-----------|-----------|---------|
| Bone fracture | 831 (5.1) | 114 (3.6) | < 0.001 |
| Malignant disease | | | |
| Lung cancer | 532 (3.3) | 176 (5.6) | < 0.001 |
| Hematological malignancy | 234 (1.4) | 71 (2.2) | < 0.001 |
| Other malignant disease | 1058 (6.5) | 231 (7.3) | 0.053 |

### Table 4 Treatment of study patients during hospitalization

| Total (%) | Death (%) | P-value |
|-----------|-----------|---------|
| Medications prescribed during hospitalization | | |
| No use of NTM drugs | 7215 (44.6) | 1504 (47.5) | < 0.001 |
| Erythromycin only | 526 (3.2) | 61 (1.9) | < 0.001 |
| RIF, EMB, CLR | 1676 (10.4) | 232 (7.3) | < 0.001 |
| RIF, EMB, CLR, +FQ and/or AG | 778 (4.8) | 188 (5.9) | 0.001 |
| Corticosteroids | 3383 (20.9) | 1069 (33.8) | < 0.001 |
| Treatment procedure | | |
| Bronchial artery embolization | 250 (1.5) | 22 (0.7) | < 0.001 |
| Mechanical ventilation | 1518 (9.4) | 957 (30.2) | < 0.001 |

# NTM drugs include the following: rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin.

# Corticosteroids include those administered both orally and intravenously.

Abbreviations: AG aminoglycoside, CLR clarithromycin, EMB ethambutol, FQ fluoroquinolone, NTM non-tuberculous mycobacterial pulmonary disease, RIF rifampicin.
development of NTM-PD [12, 13, 21–23]. In this study, patients with NTM-PD who required unscheduled hospitalization had remarkably low BMIs, the median being 17.5 kg/m². Furthermore, lower BMI was strongly associated with higher in-hospital mortality. Our findings are in line with those of other hospital-based studies assessing long-term prognosis of MAC-PD patients in Japan, which have repeatedly shown that a BMI of less than 18.5 kg/m² is associated with higher mortality [12, 13]. It is possible that most of the patients who died during their hospitalizations had cachexia, which is recognized as a complex metabolic syndrome [24].

Development of more effective anti-mycobacterial drugs may be crucial to preventing progression of NTM-PD. However, such drugs may not completely prevent progression of NTM-PD because some patients are likely to have polyclonal and mixed NTM infections acquired from the environment, as well as reinfection with NTM after treatment [25, 26]. Taken together, exploring host factors (such as the mechanisms by which severe weight loss affects susceptibility to, and progression of, NTM-PD) may be important in improving the prognosis of this disease. In fact, two previous studies have reported a possible role for inappropriately secreted adipokines in the pathogenesis of NTM-PD [27, 28]; however, their results were inconsistent and thus require further investigation.

Several limitations must be acknowledged. First, mild cases of NTM-PD without respiratory complications may have not been recorded by the attending physician; this would have resulted in low sensitivity for the diagnosis of mild cases of NTM-PD. NTM-PD is more likely to be diagnosed when it is has resulted in moderate to severe respiratory symptoms. Second, we may have underestimated the proportion of patients who were receiving combination therapy for MAC-PD because anti-mycobacterial drugs prescribed in the outpatient settings are usually withdrawn on admission in more severe cases. This would have prevented us from accurately evaluating the association between antibacterial therapies for NTM-PD and in-hospital mortality.

Conclusions
In the present study of data drawn from a nationwide inpatient database in Japan, we identified multiple factors associated with in-hospital mortality of NTM-PD. In particular, we found associations between pulmonary infection other than NTM and lower BMI and higher in-hospital mortality. Controlling for severe weight loss and comorbidities may play a key role in improving the prognosis of this disease.

| Abbreviations |
|----------------|
| BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; DPC: Diagnosis Procedure Combination; DSM-5: Diagnostic and Statistical |
Manual of Mental Disorders, Fifth Edition; ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision; IQR: Interquartile range; MAC-PD: Mycobacterium avium complex pulmonary disease; NTM-PD: Non-tuberculous mycobacterial pulmonary disease

Acknowledgements
Not applicable.

Authors' contributions
G.T. and T.J. take responsibility for the integrity of the data and have final responsibility for the decision to submit the manuscript for publication. G.T. and T.J. had full access to the data. G.T., T.J., and T.N. designed and supervised the project. H.M., K.F. and H.Y. contributed to acquisition of data. G.T., T.J., H.T., Y.S., WH., and H.Y. contributed to statistical analysis and interpretation of the results. G.T., T.J. and H.Y. drafted and finalized the manuscript. All authors have critically read, and approved, the final version of the manuscript.

Funding
This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (19AA2007 and 20AA2005) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907).

Availability of data and materials
Data cannot be made publicly available for ethical reasons as the data are patient data. The data are available to interested researchers upon reasonable request to the corresponding author, pending ethical approval.

Declarations

Ethics approval and consent to participate
Conduct of the study was approved by the Institutional Review Board of The University of Tokyo, which waived the requirement for informed consent owing to the anonymity of the data. This study was performed in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Respiratory Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. 2Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 4Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.

Received: 13 January 2021 Accepted: 14 July 2021

Published online: 20 July 2021

References
1. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. Emerg Infect Dis. 2013;19(11):1889–91. https://doi.org/10.3201/eid1911.130737.
2. Moriimoto K, Iwai K, Uchimura K, Okumura M, Yoshimura T, Hirohara K, et al. A steady increase in nontuberculous mycobacterioses mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1–8. https://doi.org/10.1513/AnnalsATS.201303-067OC.
3. Namkoong H, Kurasimha A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculosis mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1102–9. https://doi.org/10.3201/eid2206.151642.
4. Ringhausen FC, Wagner D, de Roux A, Diel R, Hohmann D, Hickstein L, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerg Infect Dis. 2016;22(6):1102–5. https://doi.org/10.3201/eid2206.151642.
5. Izumi K, Morimoto K, Hasegawa N, Uchimura K, Kawatsuki L, Ato M, et al. Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan. Ann Am Thorac Soc. 2019;16(3):341–7. https://doi.org/10.1513/AnnalsATS.201806-366OC.
6. Lee H, Myung W, Koh WJ, Moon SM, Jhun BW. Epidemiology of nontuberculosis mycobacterial infection, South Korea, 2007–2016. Emerg Infect Dis. 2019;25(3):569–72. https://doi.org/10.3201/eid2503.181597.
7. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc. 2020;17(2):178–85. https://doi.org/10.1513/AnnalsATS.201804-236OC.
8. Vinnard C, Longworth S, Mezchow A, Patrawalla A, Keswirth BN, Hamilton K. Deaths related to nontuberculous mycobacterial infections in the United States, 1999–2014. Ann Am Thorac Soc. 2016;13(1):1951–5. https://doi.org/10.1513/AnnalsATS.201606-474BC.
9. Andrejak C, Thomsen VO, Johannsen IS, Ris A, Benfield TL, Duhat P, et al. Nontuberculosis mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2018;198(5):S14–21. https://doi.org/10.1164/rccm.200905-077OC.
10. Adjemian J, Olliver KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881–6. https://doi.org/10.1164/rccm.201111-201OC.
11. Marras TK, Campitelli MA, Le H, Chung H, Brode SK, Marchand-Austin A, et al. Nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001–2013. Emerg Infect Dis. 2017;23(3):468–76. https://doi.org/10.3201/eid2303.161927.
12. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185(5):575–83. https://doi.org/10.1164/rccm.201107-120OC.
13. Kumagai S, Ito A, Hishimoto T, Marumo S, Tokunaga H, Kotani A, et al. Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study. BMC Infect Dis. 2017;17(1):436. https://doi.org/10.1186/s12879-017-2544-0.
14. Griffith DE, Ackamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. https://doi.org/10.1164/rccm.200604-51751T.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Washington, DC: American Psychiatric Association Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596.
16. Japanese Society of Tuberculosis, Japanese Society of Respiratory Diseases. Opinions on chemotherapy of non-tuberculous acid-fast bacterial infection of the lung. Kekkaku. 2012;87:35.
17. Aloisio KM, Micali N, Swanson SA, Field A, Horton NJ. Analysis of partially observed clustered data using generalized estimating equations and multiple imputation. Stata J. 2014;14(4):863–83. https://doi.org/10.1177/1753647214535088.
18. Rubin DB. Multiple imputation for nonresponse in surveys: John Wiley & Sons; 1987. https://doi.org/10.1002/9780470316696.
19. Novosad SA, Henkle E, Schafer S, Hedberg K, KU, Siegel SAR, et al. Mortality after respiratory isolation of nontuberculous mycobacteria. A comparison of patients who did and did not meet disease criteria. Ann Am Thorac Soc. 2017;14(7):1112–9. https://doi.org/10.1513/AnnalsATS.201610-8000C.
20. Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5(8):e008058. https://doi.org/10.1136/bmjopen-2015-008058.
21. Song JH, Kim BS, Kwaak N, Han KD, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2021;57(2):2000454. PMID: 32817261.
22. Kim RD, Greenberg DE, Ehmannart ME, Guide SV, Ding L, Shea Y, et al. Pulmonary nontuberculosis mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066–74. https://doi.org/10.1164/rccm.200805-686OC.
23. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, et al. Clinical significance of the differentiation between M. avium-intracellulare and
Mycobacterium intracellulare in M avium complex lung disease. Chest. 2012;142(6):1482–8. https://doi.org/10.1378/chest.12-0494.

24. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. https://doi.org/10.1016/j.clnu.2008.06.013.

25. Fujita K, Ito Y, Hirai T, Kubo T, Maekawa K, Togashi K, et al. Association between polyclonal and mixed mycobacterial Mycobacterium avium complex infection and environmental exposure. Ann Am Thorac Soc. 2014;11(1):45–53. https://doi.org/10.1513/AnnalsATS.201309-297OC.

26. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, et al. Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276–82. https://doi.org/10.1378/chest.13-2538.

27. Tasaka S, Hasegawa N, Nishimura T, Yamasawa W, Kamata H, Shinoda H, et al. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration. 2010;79(5):383–7. https://doi.org/10.1159/000231975.

28. Kartalija M, Ovrutsky AR, Bryan CL, Port GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013;187(2):197–205. https://doi.org/10.1164/rccm.201206-1035OC.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.